+39% after hours Most Active: SXTC China SXT Pharm NASDAQ 02/02/26: watch float

The SXTC stock surged in after-hours trading, rising +39.03% after a late-day spike in volume. China SXT Pharmaceuticals, Inc. (SXTC) on the NASDAQ logged volume of 675,188,643 shares versus an average of 13,023,872, driving the stock from a prior close of $0.031 to $0.0431 in after-hours trade on 02 Feb 2026. The move follows a company 1-for-150 share consolidation effective Feb 3, 2026, and left SXTC among the most active names in the session. We look at drivers, metrics, and where this trade leaves short-term and medium-term outlooks

SXTC stock: after-hours price action and drivers

SXTC stock moved sharply after hours on heavy volume and consolidation news. The official share consolidation of 1-for-150 reduces issued Class A shares from about 143.69 million to roughly 0.96 million, a structural change that typically compresses float and can amplify intraday moves.

Nasdaq coverage and market data show the stock traded between a day low of $0.0385 and a high of $0.0744 intraday, closing the regular session at $0.031 before the after-hours run. Investors should note price history ranges from a 52-week low of $0.027 to a 52-week high of $6.98, which signals prior volatility and thin liquidity spikes.

SXTC stock: fundamentals and valuation snapshot

China SXT Pharmaceuticals, Inc. lists on the NASDAQ and reports revenue per share of 0.54 with EPS of -0.23 and a negative PE of -0.19, reflecting recent losses. The company operates in Healthcare, in Drug Manufacturers – Specialty & Generic, and sells traditional Chinese medicine products.

Key ratios show a high cash buffer per share (cash per share 8.67) and a low price-to-book (PB 0.0033), while current ratio is 4.37 and debt-to-equity is 0.06. These balance-sheet figures contrast with poor profitability and very long receivable days, pointing to operational strains despite substantial reported cash per share.

SXTC stock: technicals and trading signals

Technical indicators paint a mixed, volatile picture for SXTC stock. The RSI sits at 24.63, in oversold territory, while ADX at 52.24 signals a strong trend. Price is far below moving averages; the 50-day average is 1.07 and the 200-day is 1.50, reflecting a steep multi-month decline.

Momentum indicators show deep sell pressure but a potential short-term bounce after the consolidation headline. Traders should expect wide intraday swings given the relative volume 51.84 and thin post-consolidation float.

SXTC stock: Meyka AI grade, model forecast and price targets

Meyka AI rates SXTC with a score of 63 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not financial advice.

Meyka AI’s forecast model projects a short-term monthly target of $0.64 and a 3‑year projection of $28.39. Compared with the current price of USD 0.0431, the model implies an estimated upside of +1,385.87% to the monthly target and +65,801.80% to the 3-year target. Forecasts are model-based projections and not guarantees. For trading context, we offer a conservative analyst range: a near-term target of $0.20 and an aggressive long-term target near $28.00, depending on liquidity and execution of corporate strategy.

SXTC stock: risks, opportunities and sector context

Opportunities for SXTC stock include the share consolidation, which may tighten float and enable cleaner price discovery, and any pickup in demand for traditional Chinese medicine products. The Healthcare sector can support momentum when company fundamentals improve.

Risks are material: historical volatility, negative profitability, stretched receivables, and very thin free-float after consolidation. The company’s average trading metrics show a 50-day price near 1.07 and a 200-day near 1.50, highlighting the drop from prior levels. Investors should weigh these operational and liquidity risks before adding SXTC to a portfolio.

Final Thoughts

SXTC stock stands out as one of the most active after-hours names on 02 Feb 2026 after a +39.03% post-close move tied to a 1-for-150 share consolidation and extreme volume. The headline reduced outstanding Class A shares to roughly 0.96 million, making the post-consolidation float much smaller and likely to magnify price moves. Our Meyka AI grade is 63/100 (B, HOLD) and the model projects a monthly target of $0.64 and a 3-year target of $28.39 versus the current price of USD 0.0431, implying outsized percentage moves but with very high execution risk. Traders should expect elevated volatility, confirm liquidity before entering positions, and monitor filings and trading volumes closely. For more updates and live metrics visit the Meyka AI stock page for SXTC and check primary reporting on Nasdaq and MarketWatch for corporate filings and trade data source source. Forecasts are projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.